Zoetis Inc

Zoetis insider buying signals confidence ahead of earnings: Kevin Esch’s February 6 purchase highlights strong biopharma prospects and a near‑term upside for investors.

Zoetis insider purchase signals confidence in its global animal‑health strategy, market‑access plans, and drug‑development pipeline—an insight for investors navigating commodity‑driven industry risks.